Home › NDC Lookup › Ingredients › Oxaliplatin › 00955-1733-20
💉image loading
(from DailyMed)

OXALIPLATIN 5 mg/mL Injection, Solution, Concentrate

by Winthrop U.S, a business of sanofi-aventis U.S. LLC · 1 VIAL, GLASS in 1 CARTON (0955-1733-20) / 20 mL in 1 VIAL, GLASS
NDC 00955-1733-20
🏷️ FDA NDC (as labeled) 0955-1733-20 billing pads the labeler segment with a zero
Rx only Brand Discontinued Non-controlled ⚠ Discontinued by firm
🗂️ Data synced Aug 20, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Aug 2023. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

🆔 Identity & classification

FDA NDC (as labeled) 0955-1733-20
Product NDC 0955-1733
11-digit billing NDC 00955173320
NCPDP billing unit ML — per mL (volume)
Application # NDA021759
SPL Set ID 0bef8406-8dab-0ad0-e063-6394a90a60d0
Established class (EPC) Platinum-based Drug
Chemical class Platinum-containing Compounds
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Aug 2023)
Marketing start 2015-09-01
Route INTRAVENOUS
Dosage form INJECTION, SOLUTION, CONCENTRATE
Substance OXALIPLATIN
GPI-14 21100028002030
GPI class Oxaliplatin
GCN Seq No 059163
GCN 24701
HICL code 016687
Ingredient (HICL) Oxaliplatin
HIC1 code V
Therapeutic class — broad (HIC1) Neoplasms
HIC2 code V1
Therapeutic class — intermediate (HIC2) Antineoplastic Drugs
HIC3 code V1A
Therapeutic class — specific (HIC3) Antineoplastic - Alkylating Agents
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name OXALIPLATIN 100 MG/20 ML VIAL
FDB brand name Oxaliplatin
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 0955-1733-20 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00955-1733-20. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerWinthrop U.S, a business of sanofi-aventis U.S. LLC
Application holderSANOFI AVENTIS US LLC
FDA applicationNDA021759 (NDA AUTHORIZED GENERIC)
Labeler code00955
First marketedSep 2015
Product typeHuman Prescription Drug
Portfolio2 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name OXALIPLATIN 100 MG/20 ML VIAL Ingredient Oxaliplatin
📖 What it is MedlinePlus · NLM

Oxaliplatin is used with other medications to treat advanced colon or rectal cancer (cancer that begins in the large intestine). Oxaliplatin is also used with other medications to prevent colon cancer from spreading in people who have had surgery to remove the tumor. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing cancer cells.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Oxaliplatin is a chemotherapy drug that works by damaging the DNA inside cancer cells, stopping them from growing and dividing. It's always used alongside two other drugs — fluorou...
  • Why am I getting oxaliplatin — what is it actually doing for my cancer?
  • That's called peripheral neuropathy, and it's one of the most common side effects with oxaliplatin — so you're not imagining it, and you're not alone. There are two types. The firs...
  • I keep hearing about the tingling and numbness — what's that about, and will it go away?
📖 Read our full Oxaliplatin Injection guide →
1
Nutrient depletion considerations

Oxaliplatin may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Oxaliplatin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Oxaliplatin 5 mg/mL 00781-3317-80 Sandoz 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 00781-9317-80 Sandoz 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mLthis 00955-1733-20 Winthrop 1 vial — — Discontinued —
oxaliplatin 5 mg/mL 16729-0332-03 Accord 1 vial — AP FDA listed —
oxaliplatin 5 mg/mL 25021-0233-10 Sagent 1 vial — — FDA listed —
Oxaliplatin 100 mg/20mL 31722-0358-20 Camber 1 vial — AP FDA listed —
oxaliplatin 5 mg/mL 42677-0337-10 Shandong 10 vials — AP FDA listed —
Oxaliplatin 5 mg/mL 43066-0018-01 Baxter 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 55150-0332-01 Eugia 1 vial — — FDA listed —
Oxaliplatin 5 mg/mL 60505-6132-06 Apotex 1 vial — — FDA listed —
Oxaliplatin 5 mg/mL 60505-6287-02 Apotex 1 vial — — FDA listed —
Oxaliplatin 5 mg/mL 61703-0363-18 Hospira, 1 vial — AP Discontinued —
Oxaliplatin 100 mg/20mL 67184-0509-01 Qilu 1 vial — — FDA listed —
Oxaliplatin 5 mg/mL 67457-0442-20 Mylan 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 68001-0468-36 BluePoint 1 vial — — FDA listed —
Oxaliplatin 5 mg/mL 68083-0177-01 Gland 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 71288-0101-10 Meitheal 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 71288-0149-95 Meitheal 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 71288-0172-21 Meitheal 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 72266-0162-01 FOSUN 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 72603-0101-01 NorthStar 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 72603-0320-01 Northstar 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 00955-1731-10 Winthrop 1 vial — — Discontinued —
Oxaliplatin 5 mg/mL 68083-0176-01 Gland 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 68083-0314-01 Gland 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 00781-9315-70 Sandoz 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 72603-0301-01 NorthStar 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 00781-3315-70 Sandoz 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 55150-0331-01 Eugia 1 vial — — FDA listed —
Oxaliplatin 5 mg/mL 71288-0171-11 Meitheal 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 72266-0161-01 FOSUN 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 43066-0014-01 Baxter 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 72603-0420-01 Northstar 1 vial — AP FDA listed —
Oxaliplatin 5 mg/mL 63323-0750-10 Fresenius 1 vial — AP Discontinued —
Oxaliplatin 5 mg/mL 67457-0469-10 Mylan 1 vial — AP FDA listed —
oxaliplatin 5 mg/mL 42677-0336-10 Shandong 10 vials — AP FDA listed —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2015
On the market since
Sep 2015
📍
2026
Currently FDA-listed
11 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Oxaliplatin — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Oxaliplatin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$226.2K
Claims incl. refills
835
Beneficiaries
400
Spend / beneficiary
$565.53
Spend / claim
$270.91
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
00955-1733-20 You're viewing this 1 VIAL, GLASS in 1 CARTON (0955-1733-20) / 20 mL in 1 VIAL, GLASS 2015-09-01 Discontinued by firm

🧭 About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 0955-1733-20, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 00955-1733-20, written without dashes as 00955173320. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 00955-1733-20, the first segment (00955) is the labeler code FDA assigned to Winthrop U.S, a business of sanofi-aventis U.S. LLC; the middle segment (1733) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (20) identifies this exact package size and type. Together they name one specific package of one specific product.
Who lists this product with the FDA?
Winthrop U.S, a business of sanofi-aventis U.S. LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 00955-1731-10 · Winthrop 00955-2900-02 · Sanofi-Aventis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.